{"id":"NCT01854697","sponsor":"AbbVie","briefTitle":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before","officialTitle":"A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered With and Without Ribavirin Compared to Telaprevir Co-administered With Pegylated Interferon α-2a and Ribavirin in Treatment-Naïve Adults With Chronic Hepatitis C Genotype 1 Virus Infection (MALACHITE I)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-03","primaryCompletion":"2014-11","completion":"2015-07","firstPosted":"2013-05-15","resultsPosted":"2016-02-22","lastUpdate":"2018-06-06"},"enrollment":311,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis C Infection"],"interventions":[{"type":"DRUG","name":"ABT-450/r/ABT-267, ABT-333","otherNames":["Viekira Pak","ABT-267 also known as ombitasvir","ABT-450 also known as paritaprevir","ABT-333 also known as dasabuvir","Holkira Pak"]},{"type":"DRUG","name":"Ribavirin","otherNames":[]},{"type":"DRUG","name":"Telaprevir","otherNames":[]},{"type":"DRUG","name":"Pegylated Interferon alpha 2-a (PegIFN)","otherNames":[]}],"arms":[{"label":"Arm A: 3-DAA + RBV in GT1a","type":"EXPERIMENTAL"},{"label":"Arm B: TPV/PR in GT1a","type":"ACTIVE_COMPARATOR"},{"label":"Arm C: 3-DAA + RBV in GT1b","type":"EXPERIMENTAL"},{"label":"Arm D: 3-DAA in GT1b","type":"EXPERIMENTAL"},{"label":"Arm E: TPV/PR in GT1b","type":"ACTIVE_COMPARATOR"}],"summary":"This is a study to evaluate the efficacy and safety of three experimental drugs compared with telaprevir (a licensed product) in people with hepatitis C virus infection who have not had treatment before.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment (SVR12) - Primary Efficacy Analyses","timeFrame":"12 weeks after the last actual dose of active study drug","effectByArm":[{"arm":"Arm A: 3-DAA + RBV in GT1a","deltaMin":97.1,"sd":null},{"arm":"Arm B: TPV/PR in GT1a","deltaMin":82.4,"sd":null},{"arm":"Arm C: 3-DAA + RBV in GT1b","deltaMin":98.8,"sd":null},{"arm":"Arm D: 3-DAA in GT1b","deltaMin":97.6,"sd":null},{"arm":"Arm E: TPV/PR in GT1b","deltaMin":78,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG003 vs OG004","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["26321288"],"seeAlso":["http://rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":153},"commonTop":["HEADACHE","NAUSEA","PRURITUS","FATIGUE","ANAEMIA"]}}